Kazia Therapeutics

Kazia Therapeutics said it will sell 2,580,000 ADS at $15.50 each, expecting gross proceeds of around $40m before fees. In addition, series A and series B warrants are being offered, the exercise of which could generate a further roughly $80m; exercise conditions are tied to the release of clinical trial data for certain breast cancer subtypes. The funds are intended primarily to finance the clinical development of lead candidate Paxalisib and to provide working capital. The offering, accompanied by Leerink Partners, Guggenheim, BTIG and Needham, is expected to close around August 31, 2026; the ADRs fell about 6.2% in premarket trading. » Más en de.investing.com

In an ongoing phase 1b study of Paxalisib in combination with pembrolizumab and chemotherapy, six evaluable patients with metastatic triple-negative breast cancer derived clinical benefit. Five of the six patients achieved an objective response (1 complete, 4 partial remissions; objective response rate 83%), and the remaining patient had disease stabilization; responses occurred about three months after randomization and involved, among others, lung, liver, bone, lymph node and CNS lesions. Marked median reductions in circulating tumor cell clusters (83%) and terminally exhausted T cells (51%) were observed, without serious adverse events attributed to Paxalisib. Recruitment is expected to continue until July 2027, with interim results announced for 2026 and 2027. » Más en de.investing.com

Kazia Therapeutics released preclinical data on NDL2, a potential first-in-class protein degrader designed to eliminate nuclear PD-L1. In triple-negative breast cancer models, NDL2 reduced tumor volume as monotherapy by 49% and in combination with anti-PD-1 by 73%, and reduced lung metastases by 50%. The program showed no observed toxicity; IND-enabling studies are ongoing and first clinical trials are planned for 2027, with additional data expected in 2026. » Más en de.investing.com